Well Told Grants

Federal grant recipients / California

Federal grants to Revel Pharmaceuticals Inc.

San Francisco, California · Small businesses · UEI RBFMLGKG8KZ3

Revel Pharmaceuticals Inc. in San Francisco, California received $2.9 million in federal grants from fiscal 2021 to 2025, across 6 awards. Its largest program was Aging Research, with $1.6 million. In fiscal 2025 it was awarded $1.7 million.

From USAspending.gov award records, updated November 7, 2026.

By year

Federal grants to Revel Pharmaceuticals Inc. by fiscal year
Fiscal yearAwardsAmount
FY 20210$0
FY 20220$0
FY 20232$549,760
FY 20242$670,770
FY 20252$1.7 million

An award funded in several years counts in each of them, so yearly awards add up to more than the five-year total.

Programs that fund Revel Pharmaceuticals Inc.

Every program, fiscal 2021 to 2025
ProgramAwardsAmount
Aging Research 93.8662$1.6 million
Vision Research 93.8671$358,065
Biomedical Research and Research Training 93.8591$346,678
Diabetes, Digestive, and Kidney Diseases Extramural Research 93.8471$323,833
Alcohol Research Programs 93.2731$272,118

Awarding agencies

AgencyAwardsAmount
Department of Health and Human Services6$2.9 million

Largest awards

The 6 largest awards by money obligated in fiscal 2021 to 2025
AwardProgramFirst actionAmount
Development of enzymatic tools for rapid measurement of advanced glycation and lipoxidation end product-protein adducts - project summary revel pharmaceuticals is developing an innovative, cost-effective, and user-friendly enzymatic method to measure advanced glycation and lipoxidation end products
ASST_NON_R44AG084351_075 on USAspending
Aging ResearchAugust 14, 2025$1.4 million
Development of advanced glycation end product (AGE)-breaking enzymes as a novel therapy for the treatment of diabetic retinopathy - project summary diabetic retinopathy (DR) is a major complication associated with type 1 and type 2 diabetes. Approximately 20% of patients with diabetes develop dr. Dr
ASST_NON_R43EY036695_075 on USAspending
Vision ResearchJuly 25, 2025$358,065
An enzyme-based assay for the detection of carboxyethyl lysine-protein adducts - project summary advanced glycation endproducts (AGES) are hallmarks of mammalian aging and disease. NΕ-carboxyethyl-lysine (CEL) in particular, is among the most abundant ages accumulating in tissue proteins with aging,
ASST_NON_R43GM154502_075 on USAspending
Biomedical Research and Research TrainingJuly 1, 2024$346,678
Development of advanced glycation end product (AGE)-breaking enzymes as a novel therapy for the treatment of diabetic kidney disease - project summary diabetic kidney disease (DKD) is a major complication associated with type 1 and type 2 diabetes. Approximately 25% of patients with diabetes develop
ASST_NON_R43DK137624_075 on USAspending
Diabetes, Digestive, and Kidney Diseases Extramural ResearchApril 29, 2024$323,833
Development of enzymatic tools for rapid measurement of advanced glycation end product-protein adducts - project summary advanced glycation end product (AGE) accumulation is a hallmark of mammalian aging. Ages play causative roles in various age-related diseases by interfering with cell signaling pa
ASST_NON_R43AG084351_075 on USAspending
Aging ResearchAugust 14, 2023$277,144
An enzyme-based assay for the detection of acetaldehyde-protein adducts - abstract chronic alcohol consumption is a significant issue worldwide which can lead to addiction and damage throughout the body. The first step in alcohol metabolism is its conversion into acetaldehyde, which is a highly reac
ASST_NON_R43AA030937_075 on USAspending
Alcohol Research ProgramsJuly 20, 2023$272,118

Amounts are net obligations: money committed, minus any amounts taken back. They are not payments. See how our data works.

Questions people ask

How much federal grant money does Revel Pharmaceuticals Inc. get?

$2.9 million in 6 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.

Which agency gives Revel Pharmaceuticals Inc. the most?

The Department of Health and Human Services, with $2.9 million in 6 awards.

What is Revel Pharmaceuticals Inc.'s largest federal grant?

$1.4 million under Aging Research, with its first action in the period on August 14, 2025. That counts only the money obligated in fiscal 2021 to 2025.

Which federal programs fund Revel Pharmaceuticals Inc.?

Its largest are Aging Research, Vision Research and Biomedical Research and Research Training.

Other grant recipients in San Francisco

Largest federal grant recipients in California · Federal grants in California